心力衰竭的表观遗传调节
Manisha Deogharia1, Priyatansh Gurha
1Center for Cardiovascular Genetics, Institute of Molecular Medicine and Department of Medicine, The University of Texas Health Sciences Center at Houston, Texas, USA.
Current opinion in cardiology
|April 12, 2024
概括
表观遗传修饰对于细胞对压力的反应至关重要,在心力衰竭中可以变得病态. 了解这些表观遗传变化和染色质结构是开发新心力衰竭治疗的关键.
科学领域:
- 表观遗传学和分子生物学
- 心血管研究研究心血管研究
背景情况:
- 表观遗传机制,包括染色质修饰,对于细胞对刺激的反应至关重要.
- 这些表观遗传过程的失调与心力衰竭的病理学有关.
研究的目的:
- 审查最近关于心力衰竭相关表观遗传机制的研究.
- 突出心力衰竭表观遗传学的概念进步和主要机制.
主要方法:
- 对心力衰竭中的表观遗传学的人类和小鼠模型研究的综述.
- 专注于基因组 lysine 脱甲基化酶,基因组脱甲基化酶,以及与染色质的层层 A/C (LMNA) 相互作用.
主要成果:
- 基因组 lysine 脱甲基酶在调节胎儿基因表达方面发挥作用,并且在心力衰竭中异常表达.
- 基因组脱乙酶抑制在心力衰竭中显示出相关性,HDAC6提供心脏保护.
- LMNA和3D基因组结构影响表观遗传调节和心力衰竭病理学.
结论:
- 表观遗传修饰是应对压力的反应,它们的失调有助于心力衰竭.
- 针对性心力衰竭治疗需要对结合表观遗传变化和染色质结构进行进一步的研究.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Epigenetic Regulation
31.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
Regulation of Heart Rates
1.8K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
1.8K
Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337


